CJC-1295 + GHRP-6 Stack vs Ipamorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
CJC-1295 + GHRP-6 Stack
CJC-1295 (GHRH analog) combined with GHRP-6 (potent ghrelin receptor agonist) to produce synergistic GH release via complementary mechanisms. GHRP-6's strong appetite stimulation distinguishes this from the CJC-1295 + Ipamorelin stack, making it preferred for bulking and mass-gaining protocols where caloric surplus is the goal. Produces larger GH pulses than CJC + Ipamorelin but with more pronounced appetite effects.
Full profileIpamorelin
Ipamorelin is a selective growth hormone secretagogue (GHS) and ghrelin receptor agonist. It stimulates GH release with high selectivity — minimal cortisol or prolactin elevation compared to older GHRPs. Widely used in research protocols for body composition, sleep quality, and recovery.
Full profile| CJC-1295 + GHRP-6 Stack | Ipamorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | CJC GHRP-6 combination, GH releasing stack, GHRH GHRP combination, CJC-1295 GHRP-6 | NNC 26-0161, Ipamorelin acetate |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | CJC-1295 100mcg + GHRP-6 100mcg–CJC-1295 200mcg + GHRP-6 300mcg mcg, 1–3x daily (pre-sleep, pre-workout, morning) | 100mcg–300mcg mcg, 1–3x daily (typically pre-sleep and/or pre-workout) |
| Administration | Subcutaneous injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Strong appetite stimulation (GHRP-6 dominant effect), Water retention, Tingling / numbness in extremities, Mild cortisol elevation (GHRP-6 is less selective than ipamorelin) | Water retention (mild), Tingling / numbness in extremities, Increased appetite, Headache (transient) |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: CJC-1295 + GHRP-6 Stack is research-stage, while Ipamorelin is investigational (in trials).
- Administration: CJC-1295 + GHRP-6 Stack — Subcutaneous injection; Ipamorelin — Subcutaneous injection, Intramuscular injection.
- Frequency: CJC-1295 + GHRP-6 Stack is typically 1–3x daily (pre-sleep, pre-workout, morning); Ipamorelin is 1–3x daily (typically pre-sleep and/or pre-workout).
- Research depth: this profile cites 2 sources for CJC-1295 + GHRP-6 Stack vs 3 for Ipamorelin.
How each works
CJC-1295 + GHRP-6 Stack
The GHRH + GHRP combination synergistically amplifies GH pulse amplitude compared to either agent alone. CJC-1295 elevates baseline GH via GHRH receptor signaling at the pituitary; GHRP-6 triggers pulse timing via GHS-R1a. GHRP-6's potent appetite stimulation (significantly stronger than ipamorelin) makes this combination preferred in protocols targeting caloric surplus and mass accumulation.
Ipamorelin
Ipamorelin selectively stimulates GH release via the ghrelin receptor (GHS-R1a) without significantly elevating ACTH or cortisol — the feature that distinguishes it from GHRP-6 and GHRP-2 (Raun et al., 1998, in swine/rodent models). Human data are limited: a PK study in 40 volunteers established a ~2-hour half-life (Gobburu et al., 1999), and a Phase 2 trial for postoperative ileus (Beck et al., 2014) failed its primary endpoint. It is not FDA-approved, and claims about body composition or recovery are extrapolated from GH physiology, not human outcome trials.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.